What is Chardan Capital’s Forecast for LXEO FY2025 Earnings?

Lexeo Therapeutics, Inc. (NASDAQ:LXEO) – Investment analysts at Chardan Capital decreased their FY2025 earnings per share (EPS) estimates for Lexeo Therapeutics in a report released on Tuesday, March 25th. Chardan Capital analyst G. Livshits now anticipates that the company will post earnings per share of ($3.10) for the year, down from their prior forecast of ($2.30). Chardan Capital currently has a “Buy” rating and a $25.00 target price on the stock. The consensus estimate for Lexeo Therapeutics’ current full-year earnings is ($3.14) per share.

Lexeo Therapeutics (NASDAQ:LXEO) last issued its quarterly earnings data on Monday, March 24th. The company reported ($0.78) EPS for the quarter, beating the consensus estimate of ($0.87) by $0.09.

Several other analysts have also recently weighed in on the stock. Royal Bank of Canada lowered their price objective on shares of Lexeo Therapeutics from $24.00 to $20.00 and set an “outperform” rating on the stock in a research report on Tuesday. Leerink Partners dropped their price target on Lexeo Therapeutics from $19.00 to $18.00 and set an “outperform” rating for the company in a research note on Monday. Finally, HC Wainwright reiterated a “buy” rating and set a $23.00 price objective on shares of Lexeo Therapeutics in a research report on Wednesday. Five analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Buy” and an average price target of $22.80.

Lexeo Therapeutics Stock Performance

NASDAQ:LXEO opened at $4.11 on Friday. The business’s 50-day moving average price is $4.07 and its two-hundred day moving average price is $6.63. The stock has a market cap of $135.90 million, a P/E ratio of -1.30 and a beta of 3.85. The company has a quick ratio of 5.95, a current ratio of 5.95 and a debt-to-equity ratio of 0.01. Lexeo Therapeutics has a twelve month low of $2.32 and a twelve month high of $19.50.

Institutional Investors Weigh In On Lexeo Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of LXEO. Geode Capital Management LLC lifted its position in Lexeo Therapeutics by 86.5% in the third quarter. Geode Capital Management LLC now owns 553,247 shares of the company’s stock valued at $5,003,000 after purchasing an additional 256,635 shares during the last quarter. State Street Corp raised its holdings in Lexeo Therapeutics by 29.4% during the 3rd quarter. State Street Corp now owns 253,946 shares of the company’s stock valued at $2,296,000 after buying an additional 57,674 shares during the last quarter. Frazier Life Sciences Management L.P. bought a new stake in Lexeo Therapeutics during the 3rd quarter valued at $11,307,000. Barclays PLC boosted its position in Lexeo Therapeutics by 162.2% during the 3rd quarter. Barclays PLC now owns 50,210 shares of the company’s stock valued at $454,000 after buying an additional 31,057 shares during the period. Finally, Janus Henderson Group PLC grew its holdings in Lexeo Therapeutics by 18.9% in the 3rd quarter. Janus Henderson Group PLC now owns 3,763,195 shares of the company’s stock worth $33,997,000 after acquiring an additional 599,203 shares during the last quarter. Institutional investors own 60.67% of the company’s stock.

About Lexeo Therapeutics

Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.